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Abstract
Reperfusion as a therapeutic intervention for acute myocardial infarction-induced cardiac injury itself induces
further cardiomyocyte death. β-arrestin (βarr)-biased β-adrenergic receptor (βAR) activation promotes
survival signaling responses in vitro; thus, we hypothesize that this pathway can mitigate cardiomyocyte death
at the time of reperfusion to better preserve function. However, a lack of efficacious βarr-biased orthosteric
small molecules has prevented investigation into whether this pathway relays protection against ischemic injury
in vivo. We recently demonstrated that the pepducin ICL1-9, a small lipidated peptide fragment designed from
the first intracellular loop of β2AR, allosterically engaged pro-survival signaling cascades in a βarr-dependent
manner in vitro. Thus, in this study we tested whether ICL1-9 relays cardioprotection against
ischemia/reperfusion (I/R)-induced injury in vivo.
Methods: Wild-type (WT) C57BL/6, β2AR knockout (KO), βarr1KO and βarr2KO mice received
intracardiac injections of either ICL1-9 or a scrambled control pepducin (Scr) at the time of ischemia (30 min)
followed by reperfusion for either 24 h, to assess infarct size and cardiomyocyte death, or 4 weeks, to monitor
the impact of ICL1-9 on long-term cardiac structure and function. Neonatal rat ventricular myocytes (NRVM)
were used to assess the impact of ICL1-9 versus Scr pepducin on cardiomyocyte survival and mitochondrial
superoxide formation in response to either serum deprivation or hypoxia/reoxygenation (H/R) in vitro and to
investigate the associated mechanism(s).
Results: Intramyocardial injection of ICL1-9 at the time of I/R reduced infarct size, cardiomyocyte death and
improved cardiac function in a β2AR- and βarr-dependent manner, which led to improved contractile function
early and less fibrotic remodeling over time. Mechanistically, ICL1-9 attenuated mitochondrial superoxide
production and promoted cardiomyocyte survival in a RhoA/ROCK-dependent manner. RhoA activation could
be detected in cardiomyocytes and whole heart up to 24 h post-treatment, demonstrating the stability of
ICL1-9 effects on βarr-dependent β2AR signaling.
Conclusion: Pepducin-based allosteric modulation of βarr-dependent β2AR signaling represents a novel
therapeutic approach to reduce reperfusion-induced cardiac injury and relay long-term cardiac remodeling
benefits.
Key words: Pepducin, β-arrestin, β2-adrenergic receptor, cardiac ischemia/reperfusion, cardiomyocyte

Introduction
Reperfusion has substantially reduced patient
mortality following acute cardiac ischemic events,
such as myocardial infarction (MI), but still induces
oxidative damage and further cardiomyocyte death,

contributing to ongoing risk of recurrent MI, sudden
death, heart failure, and stroke [1-3]. Thus, current
drug discovery efforts focus on mitigating
cardiomyocyte death via engagement of pro-survival
http://www.thno.org
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signaling pathways or inhibition of cardiotoxic
signaling events at the time of reperfusion. G
protein-coupled receptors (GPCRs) constitute the
largest class of drug targets, are expressed abundantly
in the heart and have been mainstays of therapeutic
investigation for the last two decades. β-adrenergic
receptors (βARs) in particular play critical roles in the
regulation of cardiac function and remodeling in
response to acute ischemic injury, classically via G
protein-dependent signaling. Both β1AR and β2AR
are expressed in cardiomyocytes and although βAR
stimulation has been shown capable of engaging
pro-survival signaling pathways in cardiomyocytes,
including epidermal growth factor receptor (EGFR),
extracellular-regulated kinase 1/2 (ERK1/2) and Akt
activation [4, 5], β1AR has also been shown to relay
cardiomyocyte death in response to ischemic injury
through either protein kinase A (PKA) or
Ca2+/calmodulin-dependent protein kinase II
(CAMKII) signaling [6, 7]. While β-blockers are used
as a standard therapy post-infarction to reduce
recurrent MI or sudden death [3], the development of
pharmacologic tools that can differentially engage
proximal βAR isoform-specific signaling pathways at
the time of injury to promote cardioprotection and
improve cardiac remodeling outcomes has been at the
forefront of recent drug discovery efforts.
It has been postulated for some time that
proximal engagement of β-arrestin (βarr)-dependent
βAR signaling in the absence of G protein activation
has the capacity to impart survival benefits in
cardiomyocytes [4, 5], but the ability to selectively
engage this pathway with small molecules to mitigate
I/R-induced myocyte death in vivo has been
challenging. Pepducins, small lipidated peptide
fragments designed from the amino acid sequences of
the intracellular loop (ICL) domains of GPCRs, were
originally shown to selectively engage proximal
signaling events via allosteric modulation of
protease-activated receptors [8]. Since their discovery,
pepducins have been demonstrated capable of
regulating an increasing cohort of GPCRs in a biased
manner and have even begun to be tested in vivo [9].
Recently, we reported the development of
β2AR-specific pepducins that selectively engage
either G protein- or βarr-dependent pathways [10]. In
particular, a cohort of pepducins based on the ICL1
region of β2AR were shown in HEK 293 cells to
induce βarr signaling, in the absence of G protein
activation, the most potent of which was ICL1-9 [11].
Subsequent analysis of ICL1-9 revealed that it
increased the activation of EGFR and ERK1/2 in HEK
293 cells and enhanced isolated adult cardiomyocyte
contractility, independent of changes in canonical G
protein-dependent signaling [11]. These results
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highlighted the ability of ICL1-9 to exert functional
responses in cardiomyocytes and suggested that it
may be capable of promoting cardiomyocyte survival
signaling. Therefore, we sought to determine whether
ICL1-9 confers cardioprotection against acute
ischemic injury and identify the mechanism(s) by
which such protection is mediated. Here, we show
that intramyocardial injection of ICL1-9 administered
at the time of injury reduces I/R-mediated infarct
size, cardiomyocyte death and improves cardiac
function acutely and long-term fibrotic remodeling.
Further, we demonstrate that although the
pro-survival effect of ICL1-9 in I/R-treated hearts is
dependent upon β2AR and βarr1 or βarr2, the
downstream survival signaling is mechanistically not
relayed via EGFR, ERK1/2 or Akt, but is dependent
instead upon the activation of RhoA. This is the first
study to demonstrate the ability of a βarr-biased
β2AR-selective allosteric modulator to promote
cardiomyocyte survival signaling and impart
structural and functional benefits following I/R,
offering a novel therapeutic approach to reduce
reperfusion-induced cardiac injury.

Methods
Experimental animals
WT C57BL/6 mice as well as β2ARKO, βarr1KO
and βarr2KO mice, all backcrossed onto a C57BL/6
background, were used in this study (equal numbers
male
and
female,
randomly
assigned
to
treatment/surgery groups, 8-12 weeks of age).
Numbers of animals used per experimental condition
are listed in figure legends. Animal procedures were
performed in accordance with the Institutional
Animal Care and Use Committee at Temple
University and in accordance to the NIH Guidelines on
the Use of Laboratory Animals.

Intracardiac injection and
ischemia/reperfusion (I/R) surgery
Three evenly spaced injections (10 μL each at a
concentration of 1 µg/µL) were administered into the
left
ventricle
(LV)
with
either
ICL1-9
(Palm-TAIAKFERLQTVTNYFIT-NH2, Peptide 2.0
Inc.) or scrambled (Scr) pepducin control
(Palm-TTKYFQTINVLFAIRATE-NH2, Peptide 2.0
Inc.). Pepducins were injected during needle
retraction to enable their administration throughout
the LV wall in both the remote zone and area at risk
(AAR) of the LV. Injections occurred ~1 min prior to
left coronary artery ligation. I/R injury was induced
as previously described [12] with the surgeon blinded
to the treatment groups. Briefly, mice were
anesthetized via 2% isoflurane inhalation, a small skin
incision was made and the pectoral muscles retracted
http://www.thno.org
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to expose the fourth intercostal space where a small
hole was formed to pop out the heart. The left
coronary artery was sutured ~2-3 mm from its origin
with a slipknot and the heart was placed back into the
intrathoracic space followed by closure of muscle and
skin. Sham animals received the same surgical
procedures without tying of the suture. After 30 min
of ischemia, the slipknot was released to allow
reperfusion of the myocardium. Animals received a
single dose (0.3 mg/kg) of buprenorphine
immediately following surgery.

LV area at risk, infarct size and
immunohistochemistry
I/R-induced injury was detected by Evans
blue/triphenyltetrazolium chloride (TTC) double
staining. Hearts were excised after 24 h reperfusion
and the ligature around the LCA was retied. Aortas
were injected with 0.2 mL of 2% Evans blue dye and
hearts were extracted and sliced into five 1.0
mm-thick sections. The sections were incubated with
1% TTC (Sigma) in phosphate buffered saline (PBS;
pH 7.4) for 5 min at 37 °C. Slices were immediately
imaged for infarct size using NIS Elements software
for recording images and image analysis. Myocardial
infarcts were imaged using NIS Elements software to
measure the unstained portion (area at risk; AAR), the
Evans blue-stained portion (area not at risk; ANAR),
the TTC-stained area (red) and TTC-negative stained
area (white; infarcted myocardium), expressed as a %
of AAR. For Masson trichrome and Wheat germ
agglutinin (WGA) staining, excised hearts were fixed
in 4% paraformaldehyde, paraffin embedded and
sectioned at 5 μm thickness. Deparaffinized sections
were stained for Masson trichrome (Sigma-Aldrich) or
wheat germ agglutinin (WGA, Vector Labs). An In
Situ Cell Death Detection Kit, TMR Red (Roche
Diagnostics; Mannheim, Germany) was used to
measure cell death via the TUNEL (TdT-mediated
dUTP-X nick end labeling) method in deparaffinized
heart sections. Deparaffinized sections were
incubated with proteinase K and DNA strand breaks
were labeled according to the manufacturer’s
instructions using tetra-methyl-rhodamine-dUTP.
Hearts were counterstained with troponin I (TNNI,
1:100; Cell Signaling; Danvers, MA) to identify
cardiomyocytes. Cells were visualized at 20X
magnification using a Nikon Eclipse microscope and
TUNEL-positive cardiomyocytes were calculated in
relation
to
the
number
of
DAPI-stained
cardiomyocyte nuclei from 10 random fields in the
ANAR and AAR.

Echocardiography
Cardiac function was performed at baseline, 1, 3,
7, 14, 21 and 28 days post-I/R via transthoracic
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two-dimensional
echocardiography
using
a
VisualSonics Vevo 2100 System with a 12 MHz probe
on mice anesthetized with isoflurane (1.5%) and body
temperature was maintained on a heated table with
embedded ECG leads to monitor heart rate,
temperature of the animal, electrocardiogram and
breathing. The parasternal short-axis views of the
heart were obtained in B-mode by placing the
transducer in the parasternal long-axis and rotating
the transducer 90° in a clockwise fashion to find the
parasternal short-axis. For measurements, M-mode
echocardiography was performed in the parasternal
short-axis view at the level of the papillary muscle to
assess several cardiac parameters including left
ventricular (LV) volumes and internal diameters (ID)
in systole (s) and diastole (d), wall thickness, LV
fractional shortening and ejection fraction. Percent
fractional shortening was calculated using the
equation (LVIDd – LVIDs) / LVIDd × 100%. Percent
ejection fraction was calculated using the equation
(LVvold – LVvols) / LVvold × 100%. The assessor was
blinded to the groups and the data was compiled into
treatment and surgical groups only after the analyses
were completed.

Primary neonatal rat ventricular myocyte
(NRVM) isolation
Primary neonatal cardiomyocytes were prepared
from 1 to 2 day old Sprague Dawley rat pups (Harlan
Laboratories; Indianapolis, IN) by manual and
enzymatic digestion. Hearts were excised and placed
in sterile ADS solution (116 mM NaCl, 20 mM HEPES,
80 μM Na2HPO4, 56 mM glucose, 5.4 mM KCl, 80 mM
MgSO4; pH 7.4). Blood and connective tissue were
removed and the ventricles were minced and
subjected to five 15 min enzymatic digestions using
collagenase II (Worthington; Lakewood, NJ) and
pancreatin. Myocytes and fibroblasts were separated
via pre-plating for 2 h. NRVM were cultured
overnight in F-10 media containing 10% horse serum,
5% fetal bovine serum (FBS) and 1% PSF at 37 °C in a
humidified incubator with 5% CO2. After 24 h, the
media was replaced with F-10 media containing 5%
FBS. At least 3 independent cell preparations were
used per experimental condition.

Radioligand binding
The density of βAR on cardiac membranes,
prepared as previously described [13], or NRVM were
determined by saturation binding experiments.
Cardiac membranes (25 μg of protein) or single cell
suspensions (1×105 cells) of NRVM were incubated
with [125I]-cyanopindolol ([125I]-CYP; 200 pM;
PerkinElmer) in binding buffer (75 mM Tris, pH 7.4, 2
mM EDTA, 12.5 mM MgCl2, 1 μg/mL aprotinin, 1
μg/mL leupeptin). Incubations were performed in the
http://www.thno.org
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presence or absence of propranolol (10 μM) to
determine non-specific binding of CGP20712A and
ICI 118,551 (100 nM) to determine βAR subtype
expression. Reactions were performed in a 250 μL
volume and allowed to equilibrate at 37 °C for 1 h
before filtering through a glass fiber filter (Whatman
GF/C; Brandel). Each filter was washed five times
with 5 mL of ice-cold wash buffer (10 mM Tris, pH
7.4, 10 mM EDTA) to remove unbound drug. The
amount of total and nonspecific radiolabel bound to
cells was determined on a gamma counter and
receptor density was normalized to cell number
(NRVM) or protein amount (cardiac membranes). All
assays were performed in duplicate.

Caspase 3/7 activity assay and TUNEL
measurements
Caspase 3/7 activity was measured using a
Caspase-Glo® 3/7 Assay according to the
manufacturer’s instructions (Promega; Madison, WI).
In brief, NRVM were plated at 10,000 cells/well in
white-walled 96-well plates. Following stabilization in
culture, cells underwent 3 h serum starvation
followed by inhibitor pre-treatment: PD98059 (10 μM
for 10 min), LY294002 (10 μM for 10 min), AG1478 (10
μM for 10 min) or rhosin (10 μM for 1 h). NRVM were
subsequently treated with Scr or ICL1-9 pepducin (10
μM each) for 24 h and 100 μL Caspase-Glo® 3/7
Reagent was added to each well. Plates were
incubated for 1 h prior to reading luminescence. For
TUNEL
assays,
NRVM
were
plated
on
fibronectin-coated
glass-bottom
dishes
and
underwent serum deprivation ± Scr or ICL1-9
pepducin treatment with or without rhosin (10 µM
each) for 24 h, following which they were fixed with
4% paraformaldehyde and underwent staining with
TUNEL (red) and DAPI (blue) as described above as
well as α-sarcomeric actin (αSrA, green; 1:500
overnight incubation (Sigma) followed by goat
anti-mouse Alexa Fluor-488 1:1000 for 1 h
(ThermoFisher)). Images were captured using a Zeiss
Axio Observer Z1 fluorescent microscope with a 40X
oil immersion lens. TUNEL-positive α-SrA-positive
cardiomyocytes were calculated as a % of the total
α-SrA-positive cardiomyocytes from 5 images per
dish.

Immunoblot analysis
Heart samples or primary cardiomyocytes were
homogenized in RIPA buffer containing 1X HALT
protease inhibitor cocktail (78437; Thermo Scientific;
Rockford, IL) and phosphatase inhibitor cocktail set
IV (524628; Calbiochem, USA). Equal amounts of
lysates were resolved by SDS-polyacrylamide gel
electrophoresis (10% gels) and transferred to
Immobilon-PSQ polyvinylidene fluoride 0.2 μm pore
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size membranes (Millipore; Billerica, MA). Odyssey
Blocking Buffer (LI-COR Biosciences; Lincoln, NE)
was used to prevent non-specific binding.
Immunoblotting was performed overnight at 4 °C
with diluted antibodies against phospho-ERK1/2
(Cell Signaling), total ERK1/2 (1:5000; Cell signaling),
phospho-Akt (1:1000; Cell Signaling), total-Akt
(1:1000; Cell Signaling), RhoA (1:500; Cytoskeleton,
Inc) or GAPDH (1:1000; Cell Signaling). After
washing with TBS-T, membranes were incubated at
room temperature for 60 min with the appropriate
diluted secondary antibody (IRDye680 Donkey
anti-rabbit IgG (H + L) at 1:20,000; IRDye800CW Goat
anti-mouse IgG (H + L) at 1:15,000; LI-COR
Biosciences; IRDye680 Donkey anti-goat IgG (H+L) at
1:20,000). Bound antibody was detected using the
LI-COR Biosciences Odyssey System (LI-COR
Biosciences).

RhoA activity assay
Activated RhoA was determined using a RhoA
Pull-Down
Activation
Assay
Biochem
Kit
(Cytoskeleton, Inc) according to the manufacturer’s
instructions. In brief, NRVM were washed with
ice-cold PBS prior to lysis or hearts were
homogenized in lysis buffer and centrifuged at 10,000
×g for 1 min to clarify samples. Equal amounts of
protein (1000 μg for NRVM and 3000 μg for hearts)
were added to 15 μg GST-Rho binding domain (RBD)
beads and incubated for 1 h at 4 °C. The beads were
washed and boiled for 2 min at 95 °C in 2X Laemmli
Buffer and samples separated by SDS-PAGE as
described above. Precipitated GTP-bound RhoA was
normalized to total RhoA and GAPDH in the whole
cell lysate (100 µg loaded).

In vitro hypoxia/reoxygenation (H/R)
NRVM were pre-treated with ICI 118,551 (100
nM for 10 min), Y-27632 (10 μM for 10 min) or rhosin
(10 μM for 1 h) prior to treatment with Scr or ICL1-9
pepducin (10 μM each). Cells were subjected to
hypoxia in Hanks Balanced Salt Solution
supplemented with 1 mM MgCl2, 2 mM CaCl2 and 10
mM HEPES under 95% N2 and 5% CO2 at 37 °C for 4 h
in the presence of inhibitors and pepducins. Cells
were then changed to fresh culture medium (F-10
media containing 5% FBS and 1% PSF) and cultured
under normoxic conditions at 37 °C with 1% O2 and
5% CO2 for 20 h.

Mitochondrial superoxide production
Mitochondrial superoxide production was
measured using MitoSOX™ in NRVM. Cells were
loaded for 10 min with 5 μM MitoSox™ in PBS with
Ca2+ and Mg2+ at 37 °C. Cells were washed three times
and counterstained with DAPI. Cells were imaged in
http://www.thno.org
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warm PBS with Ca2+ and Mg2+ at 100X magnification
on a Nikon Eclipse microscope and fluorescence was
calculated on a plate reader with excitation/emission
of 510/580 nm. MitoSOX fluorescence was
normalized to DAPI.

Statistical analysis
Data presented are expressed as mean ±
standard error of the mean (SEM). Statistical analyses
were performed using a two-tailed unpaired
Student’s t-test, a one-way ANOVA with Tukey’s
multiple comparison test or a two-way repeated
measures ANOVA with Bonferroni post test as
appropriate using Prism 5.0 software (GraphPad
Software; San Diego, CA) with n and p values
indicated in figure legends. No statistical differences
were observed between male and female animals,
thus all data is a combination of both sexes within
treatment/surgical groups.

Results
ICL1-9 reduces cardiac injury after I/R
To determine if direct cardiac administration of a
pepducin results in sustained localization within the
myocardium in vivo, we administered TMR-labeled
ICL1-9 (ICL1-9TMR) via intracardiac injection and
monitored its localization over time. Within 3 h of
injection, ICL1-9TMR localized within or just
proximal to the injection track; however, more diffuse
localization distal to the injection site was observed at
6 and 24 h (Figure 1A), both within cardiomyocytes
and interstitially, but was largely undetectable by 72 h
post-injection (not shown). We previously observed
that ICL1-9 induces β2AR internalization over time in
a HEK 293 cell receptor overexpression model [11];
therefore, we performed radioligand binding analysis
to determine whether downregulation of β2AR from
cardiac membranes occurs in response to the
long-lasting presence of ICL1-9 in the heart. Neither
β1AR nor β2AR densities were altered by ICL1-9
compared to scrambled pepducin control (Scr) 24 h
after injection (Figure 1B). Together, these data
suggest that ICL1-9 may be capable of imparting
effects in the heart that last hours to days, well within
the timeframe in which cardiac damage occurs in
response to acute ischemic injury. Thus, to determine
whether ICL1-9 administration confers protection
against acute ischemic injury, wild-type C57Bl6/J
(WT) mice were given intramyocardial injections of
either Scr or ICL1-9 pepducin followed by 30 min
ischemia and 24 h reperfusion (I/R), after which the
hearts were excised and infarct size assessed (Figure
1C). Although there was no difference in the area at
risk (AAR) between the Scr and ICL1-9 groups
(Figure 1D), ICL1-9-treated mice had a decreased
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infarct size within the AAR (Figure 1E),
correspondingly decreased cardiomyocyte death
within the AAR (Figure 1F) and reciprocally
enhanced cardiac contractility (Figure 1G).

ICL1-9-mediated cardioprotection requires
β2AR and β-arrestins
Since we previously demonstrated that
ICL1-9-induced
changes
in
isolated
adult
cardiomyocyte function were dependent upon β2AR
and βarr expression [11], we tested their requirement
for relaying the protective effect of ICL1-9 against I/R
in vivo. Cardiac AAR and infarct area values in
response to I/R were not statistically different
between the various KO mice and their WT controls
treated with Scr pepducin. However, in contrast to
WT mice, intracardiac injection of ICL1-9 was unable
to reduce infarct size or improve cardiomyocyte
survival within the AAR in β2ARKO mice (Figure
2A-E). Similarly, ICL1-9 was unable to impart
protection against I/R in either βarr1KO or βarr2KO
mice as compared to WT control mice (Figure 2F-J).
Therefore, direct intracardiac administration of
ICL1-9 imparts protection against I/R-induced
cardiomyocyte death to attenuate the acute loss of
contractile function via βarr-dependent β2AR
signaling.

ICL1-9 relays improvements in cardiac
remodeling and function after I/R
We next sought to determine whether the acute
cardioprotection offered by ICL1-9 translated to
improvements in cardiac structure and function
following I/R. WT mice that received intracardiac
injection of Scr of ICL1-9 pepducin at the time of
either sham or I/R surgery were monitored via
echocardiography for up to 4 weeks (Figure S1, Table
1 and Table 2). Analysis of LV internal diameter and
volume indicated that ICL1-9-treated hearts displayed
progressively less post-I/R dilation than Scr-treated
hearts
over
time
(Table
1).
However,
ICL1-9-mediated improvements in both fractional
shortening and ejection fraction occurred only at early
post-I/R timepoints, whereas Scr pepducin-treated
hearts were able to recover contractile function by the
end of 4 weeks. This long-term functional recovery to
I/R is similar to that observed in previous studies
using the same conditions of I/R [12, 14, 15]. Notably,
wall thicknesses were unchanged between Scr- and
ICL1-9 pepducin-treated groups (Table 2). Indeed,
gravimetric analysis showed similar changes in size of
the Scr- and ICL1-9-treated hearts at 4 weeks post-I/R
(Figure 3A), and wheat germ agglutinin staining
demonstrated similar cardiomyocyte cross sectional
area changes in response to I/R regardless of
http://www.thno.org

Theranostics 2018, Vol. 8, Issue 17

4669

Figure 1. ICL1-9 attenuates cardiac injury after I/R. (A) WT mice received an intracardiac injection of unlabeled ICL1-9 or TMR-conjugated ICL1-9 (red). Representative
heart sections from at least 4 independent mice per timepoint. Sections were stained with troponin I (TNNI, green) to identify cardiomyocytes and DAPI (blue) to label nuclei.
n=4 ICL1-9 (Unlabeled), n=5 ICL1-9TMR at each timepoint. (B) Radioligand binding analysis of βAR isoform expression in the LV of WT mice 24 h after intracardiac injection
of Scr or ICL1-9 pepducin. n=5 Scr, n=6 ICL1-9, no significant differences observed, two-tailed unpaired t-test for each isoform. (C) Representative Evan’s Blue/TTC staining of
hearts from mice receiving Scr or ICL1-9 pepducin injection followed by 30 min ischemia/24 h reperfusion (I/R). Quantification of (D) the area at risk (AAR) expressed as a
percentage of the total LV area and (E) infarct size expressed as a percentage of the area at risk. n=9 each, * p < 0.05, two-tailed unpaired t-test. (F) Representative TUNEL
staining (red) from the AAR of hearts injected with ICL1-9 or Scr control pepducin prior to I/R. Sections were counterstained with troponin I (TNNI, green) to identify
cardiomyocytes and DAPI (blue) to label nuclei and are quantified as a percentage of the TUNEL-positive cardiomyocytes in (G). n=9 each, * p < 0.05, two-tailed unpaired t-test.
(H) LV fractional shortening (FS) was measured at the short axis from M-mode using VisualSonics Analysis software. n=6 Scr Sham, n=6 ICL1-9 Sham, n=9 Scr I/R, n=10 ICL1-9
I/R, *** p < 0.001, two-way repeated measures ANOVA with Bonferroni post test.

pepducin treatment (Figure 3B-C). Although ICL1-9
treatment did not influence cardiac hypertrophy, it
conveyed a dramatic impact on fibrosis. Masson
Trichrome staining revealed a significantly reduced
fibrotic infarct scar area in ICL1-9-treated hearts as
compared to the Scr pepducin control at 4 weeks
post-I/R (Figure 3D-E), which likely reflects the
decreased cardiomyocyte death imparted by ICL1-9
immediately
following
I/R.
These
results
demonstrate that the acute cardioprotective effect of
even a single administration of ICL1-9 at the time of
I/R is sufficient to relay long-term benefits on cardiac
remodeling.

ICL1-9 protects against cardiomyocyte death
in vitro
Beyond a requirement for β2AR and either βarr1
or βarr2, the mechanism by which ICL1-9 promotes
cardiomyocyte survival is unknown. We previously
demonstrated
that
ICL1-9
increases
the
phosphorylation of EGFR and ERK1/2 in HEK 293
cells [11] and that βAR-mediated transactivation of
EGFR and downstream engagement of ERK1/2 and
Akt provides protection against cardiomyocyte death
in vitro [4]; thus, we hypothesized that this pathway
would be responsible for relaying the protective
effects of ICL1-9. In order to investigate the
http://www.thno.org
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mechanism responsible for the protective effects of
ICL1-9, we employed primary neonatal rat ventricular
myocytes (NRVM), which we initially treated with
ICL1-9 for increasing timepoints, to determine
whether it impacts βAR membrane density in
cardiomyocytes in vitro. Treatment of NRVM for
either 1 h (Figure 4A) or 24 h (Figure 4B) with ICL1-9
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did not reduce membrane density of either β1AR or
β2AR, although decreased β1AR density in response
to ISO was detected at both timepoints. These data
recapitulate our in vivo data, suggesting that ICL1-9
may be capable of imparting long-lasting effects via
regulation of
membrane-localized β2AR
in
cardiomyocytes.

Figure 2. ICL1-9-mediated protection against I/R-induced injury is β2AR- and β-arrestin-dependent. Representative images of hearts from WT controls versus
β2ARKO (A) or βarr1KO and βarr2KO (F) mice that received Scr or ICL1-9 pepducin at the time of I/R, stained with Evan’s Blue/TTC 24 h following I/R injury. Quantification
of (B, G) the area at risk (AAR) expressed as percentage of the total LV area and (C, H) infarct size expressed as a percentage of the AAR for WT controls versus β2ARKO
(B-C) or βarr1KO and βarr2KO (G-H) mouse hearts. Representative TUNEL staining (red) within the AAR of WT controls versus β2ARKO (D) or βarr1KO and βarr2KO
(I) mouse hearts. Hearts were counterstained for troponin I (TNNI, green) to label cardiomyocytes and DAPI (blue) to identify nuclei. Quantification of TUNEL+ cardiomyocytes
expressed as a percentage of the total number of cardiomyocytes for WT versus β2ARKO (E) or βarr1KO and βarr2KO (J) mouse hearts. For (A-E): n=7 Scr WT, n=7 ICL1-9
WT, n=10 Scr β2ARKO, n=11 ICL1-9 β2ARKO. For (F-J): n=18 Scr WT, n=10 ICL1-9 WT, n=10 Scr βarr1KO, n=10 ICL1-9 βarr1KO, n=11 Scr βarr2KO, n=10 ICL1-9
βarr2KO. * p < 0.05, ** p < 0.01, one-way ANOVA with Tukey’s multiple comparison test.

http://www.thno.org

Theranostics 2018, Vol. 8, Issue 17

4671

Figure 3. ICL1-9 reduces fibrotic remodeling following I/R. Cardiac remodeling responses to Scr or ICL1-9 pepducin were assessed via gravimetric and
immunohistological analyses 4 weeks post-I/R. (A) Quantification of gravimetric analysis of heart weight normalized to tibia length. n=8 Sham Scr, n=8 Sham ICL1-9, n=12 I/R Scr,
n=11 I/R ICL1-9, ns = not significant, ** p < 0.01, one-way ANOVA with Tukey’s multiple comparison test. (B) Representative wheat germ agglutinin (WGA) staining of hearts
to assess cardiomyocyte cross sectional area. (C) Quantification of cardiomyocyte size from WGA-stained hearts. n=7 Scr Sham, n=8 ICL1-9 Sham, n=12 Scr I/R, n=11 ICL1-9
I/R, ns = not significant, * p < 0.05, one-way ANOVA with Tukey’s multiple comparison test. (D) Representative Masson trichrome staining of Scr or ICL1-9 pepducin-injected
hearts following I/R injury. (E) Quantification of fibrosis from Masson trichrome-stained hearts, expressed as a percentage of the total LV area. n=8 Sham Scr, n=8 Sham ICL1-9,
n=10 I/R Scr, n=10 I/R ICL1-9, ns = not significant, ** p < 0.01, *** p < 0.001, one-way ANOVA with Tukey’s multiple comparison test.

Table 1. Echocardiographic contractile measurements

Scr Sham
n=16

Scr I/R
n=19

ICL1-9 Sham
n=16

ICL1-9 I/R
n=17

Baseline
1d
3d
7d
14 d
21 d
28 d
Baseline
1d
3d
7d
14 d
21 d
28 d
Baseline
1d
3d
7d
14 d
21 d
28 d
Baseline
1d
3d
7d
14 d
21 d
28 d

LV
Volume-systolic
(μL)
18.7±1.9
17.7±1.8
17.2±1.4
18.2±1.1
20.6±1.2
20.3±1.4
20.7±2.0
21.4±1.2
31.1±2.7
24.8±3.6
40.6±3.5
37.8±4.7
55.0±0.5
59.5±3.3
20.2±1.9
20.4±1.7
16.1±1.2
23.5±1.2
22.9±1.2
24.9±3.5
23.4±1.6
19.4±1.3
30.1±3.1
27.8±3.3
27.7±2.0*
28.3±1.7
29.1±4.2***
37.5±3.2***

LV
Volume-diastolic
(μL)
50.7±2.7
45.4±2.3
49.3±1.6
50.7±2.3
54.8±2.4
57.5±2.6
56.5±2.9
56.1±2.1
58.0±3.4
49.4±8.1
73.8±4.7
73.6±5.5
90.4±11.5
105.7±14.7
53.9±2.2
49.6±3.0
45.2±2.6
58.9±1.1
57.8±1.9
60.3±4.5
62.3±2.8
50.8±1.9
51.7±3.5
56.1±4.4
64.0±3.2
63.7±2.6
69.9±6.4*
81.3±5.5**

LVID-systolic LVID-diastolic Ejection
(mm)
(mm)
Fraction (%)
2.39±0.11
2.33±0.11
2.35±0.11
2.34±0.05
2.46±0.06
2.49±0.07
2.50±0.09
2.47±0.07
2.96±0.10
2.74±0.18
3.20±0.13
3.04±0.15
3.68±0.29
3.76±0.33
2.60±0.12
2.64±0.20
2.25±0.05
2.67±0.08
2.53±0.06
2.69±0.12
2.60±0.07
2.64±0.09
2.89±0.12
2.72±0.10
2.68±0.07*
2.80±0.08
2.94±0.10**
3.14±0.12*

3.49±0.08
3.32±0.10
3.47±0.03
3.41±0.07
3.58±0.06
3.58±0.07
3.57±0.07
3.56±0.07
3.70±0.10
3.43±0.25
3.99±0.11
3.95±0.14
4.13±0.34
4.31±0.23
3.75±0.06
3.47±0.12
3.37±0.09
3.71±0.05
3.67±0.07
3.67±0.10
3.73±0.07
3.46±0.07
3.45±0.11
3.54±0.14
3.80±0.08
3.80±0.07
3.96±0.16
4.19±0.12

65.1±1.9
60.2±1.9
63.2±2.4
64.1±1.2
62.6±1.0
65.0±1.3
63.2±1.6
63.2±1.2
40.4±1.7
41.2±3.1
44.1±2.5
50.8±2.1
46.4±4.6
51.1±4.2
64.9±2.4
59.0±2.4
63.7±0.8
62.0±1.2
63.3±1.0
58.9±2.8
60.3±1.5
64.4±1.8
48.4±2.1*
49.0±1.8*
55.3±1.4***
55.4±1.5
54.7±2.4
53.4±1.8

Fractional
Shortening
(%)
33.8±1.2
33.6±1.0
33.5±1.1
34.2±0.8
33.2±0.7
34.9±1.0
31.6±1.8
33.7±1.0
19.5±0.9
19.2±1.4
22.0±1.5
25.2±1.2
24.6±2.6
24.3±2.5
34.8±1.1
32.4±1.0
33.7±0.4
32.9±0.8
34.0±0.7
31.0±1.4
32.9±0.9
33.7±1.1
23.6±1.3
24.3±1.1*
28.5±0.9***
28.5±1.0
30.6±3.4*
27.8±1.3

Cardiac
Output
(mL/min)
15.2±0.9
16.3±1.5
14.7±1.6
16.6±1.0
16.9±0.8
18.9±0.8
18.5±0.7
15.2±0.8
12.0±0.6
11.8±1.4
15.4±0.9
16.9±0.9
18.3±0.9
21.3±1.8
16.0±0.7
15.5±2.3
13.2±0.7
19.2±0.8
19.6±1.2
18.5±1.1
19.8±0.6
14.6±0.5
12.4±0.8
14.0±1.0
17.6±0.5
17.7±1.0
19.6±2.0
22.2±1.6

Stroke
Volume (µL)

Heart Rate
(BPM)

33.4±1.7
26.9±1.2
32.0±1.1
32.9±1.6
34.1±1.4
37.3±1.5
35.8±1.1
34.2±1.5
24.5±1.1
23.5±2.8
31.4±2.1
34.9±2.1
35.4±2.0
40.9±2.8
35.3±1.4
28.9±2.1
29.1±1.6
38.5±0.9
38.0±1.4
35.3±2.0
38.3±1.6
33.6±0.9
24.4±1.1
28.2±2.2
34.9±1.3
37.1±2.0
40.8±6.0
43.8±3.5

460±9
527±15
455±34
506±15
493±8
507±9
514±9
443±10
485±11
501±7
489±12
507±10
518±9
512±12
451±9
477±16
456±2
498±15
498±15
525±16
520±10
438±9
478±12
499±13
515±5
491±10
491±29
512±12

* p < 0.05, ** p < 0.01, *** p < 0.001 versus Scr I/R at same timepoint, two-way repeated measures ANOVA with Bonferroni post test.

http://www.thno.org

Theranostics 2018, Vol. 8, Issue 17

4672

Table 2. Echocardiographic wall thickness measurements

Scr
Sham
n=16

Scr I/R
n=19

ICL1-9
Sham
n=16

ICL1-9
I/R
n=17

LVAW-syst LVAW-diastoli LVPW-systoli LVPW-diastoli
olic (mm)
c (mm)
c (mm)
c (mm)
Baseline 1.28±0.04
0.94±0.04
1.20±0.04
0.76±0.02
1d
3d
7d
14 d
21 d
28 d
Baseline
1d
3d
7d
14 d
21 d
28 d
Baseline

1.52±0.08
1.64±0.08
1.27±0.05
1.32±0.07
1.29±0.06
1.28±0.04
1.34±0.03
1.24±0.07
1.57±0.12
1.20±0.07
1.28±0.07
1.15±0.06
1.19±0.07
1.29±0.05

1.11±0.07
1.11±0.07
0.91±0.04
0.95±0.05
0.95±0.05
0.95±0.03
0.96±0.03
1.00±0.05
1.28±0.16
0.91±0.04
0.96±0.05
0.82±0.05
0.92±0.05
0.91±0.04

1.33±0.12
1.25±0.19
1.23±0.04
1.27±0.04
1.18±0.06
1.10±0.06
1.21±0.04
1.15±0.04
1.21±0.06
1.07±0.05
1.15±0.06
1.05±0.05
1.10±0.06
1.14±0.04

0.92±0.07
0.92±0.16
0.84±0.03
0.87±0.04
0.89±0.05
0.81±0.03
0.87±0.03
0.96±0.04
1.05±0.11
0.85±0.03
0.86±0.03
0.86±0.04
0.81±0.04
0.77±0.03

1d
3d
7d
14 d
21 d
28 d
Baseline

1.40±0.06
1.57±0.18
1.51±0.06
1.33±0.06
1.30±0.07
1.19±0.03
1.33±0.04

1.01±0.05
1.10±0.23
1.15±0.05
0.95±0.04
0.99±0.07
0.87±0.03
1.00±0.04

1.18±0.05
1.43±0.15
1.30±0.043
1.24±0.04
1.12±0.03
1.21±0.05
1.16±0.04

0.90±0.05
0.93±0.14
0.90±0.03
0.86±0.02
0.86±0.04
0.88±0.03
0.84±0.04

1d
3d
7d
14 d
21 d
28 d

1.43±0.07
1.43±0.16
1.41±0.06
1.34±0.08
1.14±0.09
1.29±0.06

1.13±0.07
1.17±0.12
1.02±0.04
0.94±0.04
0.78±0.02
1.01±0.05

1.25±0.06
1.41±0.08
1.16±0.04
1.09±0.05
1.11±0.07
1.12±0.05

1.04±0.06
1.05±0.07
0.86±0.04
0.84±0.03
0.89±0.09
0.78±0.05

To investigate the impact of ICL1-9 on
cardiomyocyte survival, we employed a 24 h
serum-deprivation model of stress we previously

used to induce NRVM death [4]. Serum deprivation of
NRVM for 24 h increased Caspase 3/7 activity, which
was not impacted by treatment with Scr pepducin, but
was ablated by ICL1-9 treatment (Figure 4C). To
determine if ICL1-9 promotes survival via EGFR,
ERK1/2 and/or Akt signaling, serum-deprived
NRVM were co-incubated with inhibitors of each
pathway, including PD98059 (upstream MEK1/2
inhibitor), LY294002 (upstream PI3K inhibitor) and
AG1478 (EGFR inhibitor) and in each case,
ICL1-9-mediated protection of NRVM was not
blocked (Figure 4D). Further, we could not detect a
significant
increase
in
ERK1/2
or
Akt
phosphorylation at any timepoint measured after
stimulation of either NRVM or mouse hearts with
ICL1-9 (Figure S2), revealing that ICL1-9 does not
engage EGFR, ERK1/2 or Akt signaling to mediate its
cardioprotective effects in cardiomyocytes in vitro or
in whole heart in vivo.

ICL1-9 relays cardiomyocyte survival via RhoA
activation
Previous work by others demonstrated that
GPCR-mediated pro-survival effects in cardiomyocytes can be relayed via activation of RhoA [16-19];
thus, we tested whether ICL1-9 activates RhoA in
cardiomyocytes. Activated RhoA (GTP-bound RhoA)
immunoprecipitations were performed using NRVM
treated with Scr or ICL1-9 pepducin for either 5 min

Figure 4. ICL1-9 protects against cardiomyocyte death in vitro. 125I-cyanopindolol binding analysis of NRVM treated for 1 h (A) or 24 h (B) with Veh, ISO, Scr or ICL1-9
pepducin (10 μM each). n=4 Veh, n=4 ISO, n=5 Scr, n=5 ICL1-9. *p < 0.05, *** p < 0.001 for β1AR density, one-way ANOVA with Tukey’s multiple comparison test. (C) Caspase
3/7 activity was measured in NRVM subjected to 24 h with or without serum in the presence of Scr or ICL1-9 pepducin (10 µM each) with values represented as a percentage
of no serum Veh control. n=7 Veh, n=7 Veh no serum, n=10 Scr no serum, n=10 ICL1-9 no serum. ns = not significant, ** p < 0.01, *** p < 0.001, one-way ANOVA with Tukey’s
multiple comparison test. (D) Caspase 3/7 activity was measured in NRVM subjected to 24 h without serum in the presence of Scr or ICL1-9 pepducin (10 µM each) and
pretreated with PD98059, LY294002 or AG1478 (10 µM each) with values represented as a percentage of Veh Scr. n=18 Veh Scr, n=20 Veh ICL1-9, n=10 PD98059 Scr and
PD98059 ICL1-9, n=8 for all other treatment groups. ns = not significant, ** p < 0.01, *** p < 0.001, one-way ANOVA with Tukey’s multiple comparison test.
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or 24 h, revealing significantly increased RhoA
activation in response to ICL1-9, an effect completely
prevented by incubation of the cells with the
β2AR-selective inverse agonist ICI 118,551 (Figures
5A-B). Further, RhoA activation was increased in WT
mouse hearts 24 h following intracardiac injection
with ICL1-9, but not Scr pepducin, an effect that was
absent in β2ARKO mouse hearts (Figure 5C). To
determine whether RhoA inhibition would prevent
ICL1-9-mediated protection of cardiomyocytes from
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serum deprivation-induced cell death, we assessed
the percentage of TUNEL-positive cardiomyocytes
treated with ICL1-9 or Scr pepducin in the presence or
absence of the small molecule RhoA inhibitor Rhosin.
Indeed,
while
ICL1-9
decreased
serum
deprivation-induced cardiomyocyte TUNEL staining,
incubation with Rhosin completely blocked this effect
(Figures 6A-B), as well as prevented the
ICL1-9-mediated reduction in caspase 3/7 activation
(Figure 6C).

Figure 5. ICL1-9 activates RhoA in cardiomyocytes and whole heart. RhoA activation was assessed via anti-GTP-bound RhoA pulldown in NRVM pretreated with Veh
or 100 nM ICI 118,551 and stimulated with Scr or ICL1-9 pepducin for 5 min (A) or 24 h (B), or in left ventricular lysates of WT or β2ARKO mice 24 h after intracardiac injection
(C). Activated RhoA (IP) was normalized to total RhoA/GAPDH (input) and expressed in histograms as fold change from Veh Scr (A-B) or WT Scr (C). For (A): n=7 Veh Scr,
n=6 Veh ICL1-9, n=5 ICI Scr and n=6 ICI ICL1-9; for (B): n=9 Veh Scr and Veh ICL1-9, n=4 ICI Scr and ICI ICL1-9; for (C): n=14 WT Scr, n=16 WT ICL1-9, n=13 β2ARKO Scr,
n=14 β2ARKO ICL1-9. * p < 0.05, one-way ANOVA with Tukey’s multiple comparison test.

Figure 6. RhoA inhibition prevents ICL1-9-mediated cardiomyocyte survival. NRVM underwent serum deprivation for 24 h in the presence or absence of ICL1-9 or
Scr pepducin with or without Rhosin (10 µM each). Cells were fixed, stained for TUNEL, DAPI and αSrA (A) and TUNEL-positive cardiomyocytes (arrowheads) were quantified
as a percentage of total cardiomyocytes (B). n=27 Veh+Scr, Veh+ICL1-9, n=24 Rhosin+Scr, n=25 Rhosin+ICL1-9 (number of fields of view assessed from 5 plates per treatment
and 3 independent primary NRVM isolations). ns = not significant, * p < 0.05, one-way ANOVA with Tukey’s multiple comparison test. (C) Caspase 3/7 activity was measured
in NRVM subjected to 24 h without serum in the presence of Scr or ICL1-9 pepducin (10 µM each) and pretreated with Rhosin (10 µM) with values represented as a percentage
of Veh Scr. n=9 Veh Scr, n=8 for all other groups. ns = not significant, * p < 0.05, one-way ANOVA with Tukey’s multiple comparison test.
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ICL1-9 reduces
hypoxia/reoxygenation-induced caspase
activation and mitochondrial superoxide
formation via RhoA/ROCK activation in
cardiomyocytes
Since acute ischemic injury results in
cardiomyocyte death due to enhanced mitochondrial
oxidative stress [20], we sought to determine whether
ICL1-9 acts to reduce this response. Thus, we used an
in vitro model of hypoxia-reoxygenation (H/R, [19])
to mimic in vivo I/R. H/R-exposed NRVM displayed
increased Caspase 3/7 activity (Figure 7A) and
mitochondrial superoxide formation (Figure 7C) that
were each significantly reduced by ICL1-9 but not Scr
pepducin. The ICL1-9-mediated protection against
both Caspase 3/7 activity (Figure 7B) and
mitochondrial superoxide formation (Figure 7D-E)
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was blocked by co-incubation with either ICI 118,551
or Rhosin. Further, since the downstream RhoA
effector ROCK was shown previously to relay
RhoA-dependent survival signaling [16, 19], we tested
whether inhibition of ROCK with its small molecule
inhibitor Y-27632 would prevent ICL1-9-mediated
pro-survival effects. Indeed, the ICL1-9-mediated
protection against both Caspase 3/7 activity (Figure
7B) and mitochondrial superoxide formation (Figures
7D-E) was blocked by co-incubation with Y-27632.
Altogether, our study shows for the first time that
direct administration of a β-arrestin-biased
β2AR-selective pepducin promotes cardiomyocyte
survival via RhoA/ROCK activation to prevent
adverse cardiac remodeling in response to acute
ischemic injury.

Figure 7. ICL1-9 decreases H/R-induced caspase 3/7 activity and superoxide formation in cardiomyocytes via RhoA/ROCK activation. NRVM underwent
hypoxia for 4 h followed by reoxygenation for 20 h in the presence of Veh, Scr or ICL1-9 pepducin (10 µM each) with or without pretreatment with ICI 118,551 (100 nM),
Y-27632 (10µM) or Rhosin (10 µM). Caspase 3/7 activity (A-B) was assessed as in Figure 5 and superoxide formation (C-D) was measured using mitosox red. Values are
expressed as a percentage of H/R Veh (A, C) or Veh Scr (B, D). For (A): n=9 for all treatment groups, for (B): n=12 for all treatment groups, for (C): n=8 Veh and H/R Veh,
n=14 H/R Scr and H/R ICL1-9, for (C): n=14 for Veh Scr and Veh ICL1-9, n=8 for all other treatment groups. ns = not significant, * p < 0.05, *** p < 0.001, one-way ANOVA with
Tukey’s multiple test. (E) Representative images of mitoSOX staining (red) in NRVM with or without H/R (left panels) or H/R plus Veh, ICI 118,551 (100 nM), Y-27632 (10µM)
or Rhosin (10 µM) and Scr or ICL1-9 pepducin (10 µM each, right panels). Cells were counterstained with DAPI (blue) to detect nuclei. n=5 for Veh No H/R and Veh H/R, n=6
for Veh H/R Scr and Veh H/R ICL1-9, n=4 for all other H/R treatment groups.
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Discussion
Targeting GPCRs to treat I/R-induced cardiac
injury has been a mainstay of therapeutic research for
decades. The activation or inhibition of numerous
cardiac GPCRs, including adenosine, adrenergic,
apelin, formyl peptide, opioid, relaxin, sphingosine 1
phosphate and urocortin receptors, have been
investigated for their potential cardioprotective
effects following I/R-induced injury [17, 21-29].
Recently, research efforts have focused more precisely
on harnessing the potential of biased signaling,
wherein distinct proximal signaling branches of
GPCRs, such as G protein- versus βarr-dependent
pathways,
may
be
engaged
to
promote
cardioprotection. For instance, recent work described
the impact of a formyl peptide receptor (FPR) ligand
that acts in a biased manner to promote ERK1/2- and
Akt-associated survival signaling with reduced
pro-death Ca2+ signaling, which conferred greater
improvement in post-I/R outcomes in vivo compared
to a conventional FPR ligand [23]. With regard to
βarr-dependent signaling, it has been known for some
time that βAR stimulation relays pro-survival effects
via engagement of βarr [5, 30] and, therefore, may
represent a novel therapeutic pathway to mitigate
I/R-induced myocyte death; however, the ability to
promote this pathway with orthosteric ligands to test
this theory in vivo has been challenging. Here, we
demonstrate for the first time that pepducin-mediated
allosteric
modulation
of
β2AR
engages
βarr-dependent cardioprotection against acute
I/R-induced injury in vivo to relay structural and
functional benefits. Thus, this signaling paradigm
represents a bona fide therapeutic strategy to promote
cardiac survival signaling at the time of I/R injury.
We previously demonstrated that ICL1-9
enhanced the activation of known survival signaling
pathways in a βarr1- and βarr2-sensitive manner in a
HEK 293 cell model with heterologous overexpression
of β2AR, and that ICL1-9 could increase isolated adult
cardiomyocyte contractility, which was dependent
upon endogenous expression of β2AR and sensitive to
the deletion of either βarr1 or βarr2 [11]. These results
suggested that ICL1-9 may be capable of engaging
pro-survival signaling in vivo to relay protection
against I/R-induced myocyte death via an
endogenous βarr-dependent β2AR pathway. Our
current study confirms this paradigm as ICL1-9 was
unable to reduce infarct size and cardiomyocyte death
in response to I/R in mice lacking expression of β2AR,
βarr1 or βarr2. With regard to these genetic mouse
models, we observed that β2ARKO mice are as
susceptible to I/R-induced injury as WT mice, which
aligns with previous studies demonstrating that
β2ARKO mice are not protected, or are even more
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susceptible to injury and death, from either
permanent coronary ligation-, catecholamine- or
anthracycline-induced cardiac toxicity [6, 31, 32].
However, in contrast to a recent study in which
βarr2KO mouse hearts experienced less damage
following I/R than WT hearts [33], in our study
neither βarr1KO nor βarr2KO mice exhibited a
statistically significant difference in I/R-induced
injury compared to WT mice. Notably, the authors of
the previous study modeled I/R using an ex vivo
Langendorff perfusion system in which they could
assess readouts of cardiac damage only at early
timepoints (minutes to hours), while our in vivo
assessment occurred 24 h post-I/R in vivo. In
addition, others have reported that βarr1KO mice
exhibit less cardiac cell death 24 h post ischemic injury
[34], though infarct sizes and function were not
assessed at this timepoint and the study employed
permanent coronary ligation, making comparisons
between the models difficult. Regardless of these
disparate outcomes with regard to the potential
impact of isoform-selective deletion of βarr on the
response to acute ischemic injury, we definitively
show here that the ability of ICL1-9 to relay acute
cardioprotection against I/R-induced injury in vivo
occurs via βarr-dependent β2AR signaling since
deletion of any one of β2AR, βarr1 or βarr2 was
sufficient to abolish the effect.
Previous work, including our own, has shown
that βarr-dependent βAR signaling mediates
cardiomyocyte survival via transactivation of EGFR
with subsequent downstream activation of ERK1/2
and Akt [4, 5, 35]. Since we had demonstrated that
ICL1-9 activated EGFR and increased ERK1/2
phosphorylation for hours in a HEK 293 cell model
[11], we postulated that its cardioprotective effect
against I/R would be relayed via this mechanism.
However, we were unable to detect a significant
increase in phosphorylation of either ERK1/2 or Akt
at multiple timepoints following treatment of primary
cardiomyocytes or injection of mouse hearts with
ICL1-9. Further, antagonists of EGFR, ERK1/2 and
Akt signaling pathways were completely unable to
prevent
ICL1-9-mediated
protection
against
pro-death caspase 3/7 activation in NRVM
undergoing serum deprivation. However, GPCR
signaling paradigms characterized in HEK 293 cell
models do not necessarily translate to those used in
cardiomyocytes, possibly due to factors including
distinct expression and localization patterns of the
GPCRs themselves or their downstream signaling
components [4, 36].
Therefore, an unrecognized βarr-dependent
molecular pathway was responsible for promoting
cardiomyocyte survival downstream of β2AR, which
http://www.thno.org
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we postulated to be mediated via RhoA activation
based on the following lines of evidence: 1) previous
work by Brown and colleagues detailed the ability of
RhoA to promote cardiomyocyte survival, either via
cardiomyocyte-specific low-level expression of
constitutively active RhoA or in response to
sphingosine-1-phosphate (S1P) stimulation of the S1P
receptor 3 [17-19]; 2) several studies, albeit in HEK 293
cells, have shown that angiotensin type 1A
receptor-mediated regulation of RhoA activity is
βarr-sensitive [37-39]; and 3) β2AR stimulation was
shown to induce βarr2-dependent membrane
translocation of p115RhoGEF and subsequent
activation of RhoA, also in HEK 293 cells [40]. Thus,
we tested whether ICL1-9-mediated pro-survival
effects in cardiomyocytes were sensitive to inhibition
of RhoA. Indeed, treatment with ICL1-9 induced
activation of RhoA in cardiomyocytes and in whole
heart, and, although we had not detected an
ICL1-9-mediated increase in ERK1/2 or Akt
phosphorylation at any timepoint, RhoA activation
occurred rapidly and was sustained for at least 24 h
both in vitro and in vivo. This activation was essential
to the promotion of cardiomyocyte survival since
inhibition or deletion of β2AR prevented
ICL1-9-mediated RhoA activation and protection
from ischemia in response to H/R in vitro or I/R in
vivo. Further, although the exact biochemical nature
by which pepducins induce signaling at their
receptors remains elusive [41], Rhosin-mediated
inhibition of RhoA activation by ICL1-9 is consistent
with βarr-dependent regulation of a RhoGEF since
Rhosin directly targets the RhoGEF binding domain
of RhoA [42], though the RhoGEF in question remains
to be identified in future studies. We additionally
observed that inhibition of the RhoA effector ROCK
also prevented ICL1-9-mediated pro-survival effects
in cardiomyocytes, consistent with other reports [16,
19], though the molecular determinants downstream
of ROCK remain to be identified in future studies. In
all, our data supports a mechanism by which
βarr-biased β2AR stimulation leads to prolonged
activation of RhoA to confer cardioprotection against
ischemic injury.
An additional unexpected observation in our
study was the lack of β2AR downregulation induced
by ICL1-9 treatment. We had previously shown in
HEK 293 cells that ICL1-9 caused β2AR
internalization [11]; however, in both isolated
cardiomyocytes and in whole heart, ICL1-9 did not
alter β2AR levels, even though the canonical
non-selective βAR agonist ISO was able to reduce the
level of β1AR after stimulation. Since ICL1-9 acted as
a partial agonist for internalization in the HEK 293 cell
model with β2AR overexpression [11], this result
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could be due to an undetectable or negligible loss of
endogenous levels of cardiac β2AR, which others
have recently shown to be expressed at low or
sporadic levels in adult cardiomyocytes [43].
Alternatively, the allosteric modulation of β2AR by
ICL1-9 in cardiomyocytes may result in the
engagement of a conformation of βarr that
preferentially promotes pro-survival signaling over
time at the expense of appreciable receptor loss. This
notion would fit with current interpretations of
GPCR-βarr interaction wherein specific intracellular
phosphorylation residues on the receptor are
differentially
induced
by
distinct
ligands/
modulators, which in turn promote unique
βarr-assembled scaffolds [44, 45]. Thus, ICL1-9 likely
induces a preference for a distinct β2AR-dependent
βarr signaling module in cardiomyocytes that
includes a RhoGEF, as discussed above, rather than
components of endocytic machinery. Further, ICL1-9
localization within the heart and cardiomyocytes for
at least 24 h after treatment, corresponding with
sustained activation of RhoA and decreased cell
death, offers an explanation as to how a single
intramyocardial injection of ICL1-9 at the time of I/R
led to both immediate improvements in cardiac
function and decreased fibrotic remodeling over time.
Thus,
ICL1-9
acts
primarily
to
maintain
cardiomyocyte survival through reperfusion/
reoxygenation, thereby leading secondarily to
improvements in cardiac function and fibrotic
remodeling. Future studies should address whether
single or repeated administrations of ICL1-9 after
injury offers further functional benefit, or if the 24 h
post-I/R window is the only timeframe in which it
can relay its benefits via acute cardiomyocyte
retention.
Until now the in vivo, and even early clinical,
use of pepducins has been focused on those targeting
GPCRs expressed in easily accessible cells and
compartments, including platelets and the liver, in
which intravenous administration of pepducins
results in sufficient uptake into the desired tissues [8,
46, 47]. As such, a potential limitation of the use of
ICL1-9 in particular for prevention of cardiac injury is
its method of delivery. In this study we used direct
intramyocardial injections to allow the greatest
accumulation of the pepducin within the
myocardium, which diffused away from the injection
site over time, ultimately enhancing cardiomyocyte
survival in response to I/R. However, the ability of
ICL1-9 to diffuse from the bloodstream through the
endothelial cell layer and into the cardiac muscle
following intracoronary delivery at the time of
reperfusion, and its resulting efficacy in comparison
to direct intramyocardial injection, is as yet untested.
http://www.thno.org
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Thus, development of small molecules to allosterically
promote βarr-dependent β2AR signaling in a similar
fashion to ICL1-9 could offer an improved approach
for a more generalized systemic delivery. Regardless,
this study shows for the first time that allosteric
engagement of βarr-biased β2AR signaling via
pepducin administration at the time of ischemic
injury in vivo promotes cardiomyocyte survival,
thereby relaying structural and functional benefits,
and represents a desirable and specific therapeutic
target for cardioprotection.
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